OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead
to better treatment tolerability in older patients, while the benefits of treatment can be
the same. The trial population consists of 30 patients aged 65 years or older, who are
starting treatment with one of these anti cancer tablet treatments: pazopanib, olaparib,
lenvatinib, sunitinib or palbociclib. The control group (half of the participants) will be
treated with the standard-of-care, the interventional group will start with the lowest dose
of the anti cancer tablets as described in the drug label. The dose will be increased every
two weeks in case of good tolerability. Results of this pilot study will be used to inform
the design of the larger randomised phase 2 trial.